Emerging therapies for acute myeloid leukemia
Abstract Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated cl...
Main Authors: | Caner Saygin, Hetty E. Carraway |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-04-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-017-0463-6 |
Similar Items
-
Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy
by: Kasey J. Leger, et al.
Published: (2023-12-01) -
CPX‐351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report
by: Ruth M. Urbantat, et al.
Published: (2021-04-01) -
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
by: Xiaoyan Liu, et al.
Published: (2019-10-01) -
Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
by: Vladan Vucinic, et al.
Published: (2020-09-01) -
CPX-351 in FLT3-mutated acute myeloid leukemia
by: Claire Andrews, et al.
Published: (2023-11-01)